Prosecution Insights
Prosecution Insights
130 pending office actions • 53 art units • 111 examiners • 1 of 130 (1%) have an AI response strategy ready • 164 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 42 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 42 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 11 (8%) |
| §103 only | 34 (26%) |
| §102 only | 2 (2%) |
| §112 only | 17 (13%) |
| Double-patenting only | 9 (7%) |
| Double-patenting + other | 18 (14%) |
| Multi-statute (no §101) | 36 (28%) |
| No statute on record | 3 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 3 | 65.8% | +34.8% |
| WILSON, MICHAEL C | 3 | 41.4% | +17.5% |
| XU, XIAOYUN | 3 | 59.9% | +31.9% |
| LI, RUIXIANG | 2 | 59.4% | +19.1% |
| THOMPSON, CURTIS A | 2 | 61.9% | +50.1% |
| FRITCHMAN, REBECCA M | 2 | 45.7% | +35.8% |
| MEYERING, SHABANA SHABBEER | 2 | 69.7% | +41.8% |
| ALLEN, MARIANNE P | 2 | 60.2% | +18.2% |
| MERTZ, PREMA MARIA | 2 | 71.6% | +35.6% |
| ARON, KIMBERLY A | 2 | 54.7% | +34.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19187394 | SYSTEMS AND METHODS FOR A REGULATORY-COMPLIANT AUTOMATED ASSAY | THOMPSON, CURTIS A | 46d overdue |
| 18237210 | SITE-SPECIFIC QUANTITATION OF DRUG CONJUGATIONS | PUTTLITZ, KARL J | 46d overdue |
| 17948496 | METHODS FOR CHARACTERIZING HOST-CELL PROTEINS | BERKELEY, EMILY R | 32d overdue |
| 18349012 | METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R ANTAGONIST | HECK, BRYAN WILLIAM | 28d overdue |
| 18336148 | SYSTEMS AND METHODS FOR DRUG DELIVERY TO OCULAR TISSUE | MEDWAY, SCOTT J | 25d overdue |
| 17854589 | Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors | VYAS, KEYUR ANILKUMAR | 19d overdue |
| 18164171 | MEDICAL DEVICE PACKAGING AND RELATED METHODS | REYNOLDS, STEVEN ALAN | 5d overdue |
| 17954999 | ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS | EVANS, CHRISTOPHER RYAN | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17676338 | NON-HUMAN ANIMALS HAVING AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION THAT INCLUDES AN ENGINEERED DIVERSITY CLUSTER AND USES THEREOF | WILSON, MICHAEL C | 100d overdue |
| 19187394 | SYSTEMS AND METHODS FOR A REGULATORY-COMPLIANT AUTOMATED ASSAY | THOMPSON, CURTIS A | 46d overdue |
| 17684674 | SYSTEMS AND METHODS FOR QUANTIFYING AND MODIFYING PROTEIN VISCOSITY | XU, XIAOYUN | 31d overdue |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | KIM, YUNSOO | 8d |
| 18182323 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | ALLEN, MARIANNE P | 27d |
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | 43d |
| 17870368 | NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY | XU, XIAOYUN | 55d |
| 18129923 | G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | MEYERING, SHABANA SHABBEER | 62d |
| Art Unit | Apps |
|---|---|
| 1643 | 7 |
| 1641 | 6 |
| 1677 | 5 |
| 1674 | 5 |
| 1642 | 5 |
| 3783 | 5 |
| 1634 | 5 |
| 1638 | 4 |
| 1647 | 4 |
| 1633 | 4 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19345987 | COMPETITIVE LIGAND BINDING ASSAYS | TRAN, CHAU NGUYEN BICH | 1677 | §103DP | Final Rejection | — | Pending | Sep 30, 2025 |
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | 1674 | §103 | Non-Final OA | 43d | Pending | Sep 18, 2025 |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | KIM, YUNSOO | 1641 | §112Other | Non-Final OA | 8d | Pending | Jun 25, 2025 |
| 19217541 | PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION | KIM, YUNSOO | 1641 | §102DP | Non-Final OA | — | Pending | May 23, 2025 |
| 19187394 | SYSTEMS AND METHODS FOR A REGULATORY-COMPLIANT AUTOMATED ASSAY | THOMPSON, CURTIS A | 1798 | §101§103 | Final Rejection | 46d overdue | Pending | Apr 23, 2025 |
| 19187429 | SYSTEMS AND METHODS FOR A REGULATORY-COMPLIANT AUTOMATED ASSAY | THOMPSON, CURTIS A | 1798 | §103 | Final Rejection | — | Pending | Apr 23, 2025 |
| 19091049 | SYSTEMS AND METHODS FOR IDENTIFYING EVENTS IN SUPPLY CHAIN PROCESSES | ANDERSON, FOLASHADE | 3623 | §101§102§103 | Non-Final OA | — | Pending | Mar 26, 2025 |
| 18945863 | SYSTEMS AND METHODS FOR PRODUCING SMALL-SCALE MIXERS FOR DRUG MANUFACTURING | PATEL, VISHAL I | 1746 | §103 | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18802201 | NON-HUMAN ANIMALS HAVING A HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3 | WRIGHT, ERIC BRANDON | — | §112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18798198 | Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors | KONOPKA, CATHERINE ANNE | 1635 | DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18766891 | HUMANIZED T CELL CO-RECEPTOR MICE | WEHBE, ANNE MARIE SABRINA | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18763490 | METHODS AND COMPOSITIONS FOR MODIFYING A TARGETED LOCUS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18673492 | SYSTEMS AND METHODS FOR FAILURE MODE DETECTION IN PROCESS CHROMATOGRAPHY | HUANG, RYAN | 1777 | §103§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18674399 | METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS | HOWARD, ZACHARY C | 1674 | §112Other | Non-Final OA | — | Pending | May 24, 2024 |
| 18669172 | Anti-CTLA-4 Antibodies and Uses Thereof | ROONEY, NORA MAUREEN | — | §112DP | Non-Final OA | — | Pending | May 20, 2024 |
| 18666742 | AUTO-INJECTOR AND RELATED METHODS OF USE | EGLOFF, PETER RICHARD | — | §102§103 | Non-Final OA | — | Pending | May 16, 2024 |
| 18659538 | SYSTEMS AND METHODS FOR REDUCING SAMPLE SIZES | ERICKSON, BENNETT S | 3683 | §101§103 | Non-Final OA | — | Pending | May 09, 2024 |
| 18606302 | Proteomic Risk Score For Osteoarthritis (OA) | FRITCHMAN, REBECCA M | — | §101§103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18603862 | SYSTEMS AND METHODS FOR IDENTIFYING EVENTS IN SUPPLY CHAIN PROCESSES | GARCIA-GUERRA, DARLENE | 3625 | §101§103 | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18582159 | Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) | KAPUSHOC, STEPHEN THOMAS | 1683 | DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18436306 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | GONZALEZ, LUISALBERTO | 1624 | §112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18432780 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | — | §112Other | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18421326 | Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors | MEYERING, SHABANA SHABBEER | — | §102§103§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18420090 | SYSTEMS AND METHODS FOR MOBILE AND STATIC BIOMETRIC MOVEMENT TRACKING | DING, XIAOMAO | 2676 | §103 | Final Rejection | 1d overdue | Pending | Jan 23, 2024 |
| 18580810 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ALLEN, MARIANNE P | — | §112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18413096 | RODENTS HAVING A HUMANIZED TMPRSS GENE | VIVLEMORE, TRACY ANN | 1638 | §112DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18572930 | ANTI-EGFRvIII ANTIBODY DRUG CONJUGATES AND USES THEREOF | HADDAD, MAHER M | — | §102§103§112DP | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18528268 | METHODS TO CHARACTERIZING A FRAGMENT CRYSTALLIZABLE DOMAIN OF A BISPECIFIC ANTIBODY | RAMADAN, OMAR | 1678 | §102§103§112 | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18510900 | Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors | HUDSON, AMY ROSE | 1636 | DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18509030 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | HUYNH, PHUONG N | 1641 | §112DP | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18559009 | Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof | LANDSMAN, ROBERT S | 1647 | §112DP | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18495182 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST | MERTZ, PREMA MARIA | 1674 | DP | Final Rejection | — | Pending | Oct 26, 2023 |
| 18488316 | HSD17B13 VARIANTS AND USES THEREOF | ZAHORIK, AMANDA MARY | 1636 | §112 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18484777 | METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME | ARON, KIMBERLY A | 1633 | DP | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18374492 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | BUNKER, AMY M | 1684 | §102§112DP | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18367444 | AN AQUEOUS PHARMACEUTICAL FORMULATION INCLUDING A VEGF RECEPTOR FUSION PROTEIN | LOCKARD, JON MCCLELLAND | 1647 | §112 | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18462320 | METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | TAYLOR, LIA ELAN | 1641 | §103Other | Non-Final OA | 8d | Pending | Sep 06, 2023 |
| 18237210 | SITE-SPECIFIC QUANTITATION OF DRUG CONJUGATIONS | PUTTLITZ, KARL J | 1646 | §103§112 | Final Rejection | 46d overdue | Pending | Aug 23, 2023 |
| 18547150 | METHOD FOR DIAGNOSING AND TREATING PARTIAL LIPODYSTROPHY | TOTH, KAREN E | 3791 | §101§102§103§112 | Non-Final OA | 83d | Pending | Aug 18, 2023 |
| 18264799 | METHODS OF TREATING CANCER BY ADMINISTERING A NEOADJUVANT PD-1 INHIBITOR | SULLIVAN, DENNIS JOHN | 1642 | §103§112DP | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18229117 | Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies | JOHANSEN, PETER N. | 1645 | §102§103DP | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18355108 | Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof | SCHWECHTER, BRANDON ROSS | 1674 | §102§112 | Non-Final OA | 34d | Pending | Jul 19, 2023 |
| 18221934 | ISOELECTRIC FOCUSING-BASED ENRICHMENT OF CHARGE VARIANT SPECIES | FRITCHMAN, REBECCA M | 1758 | §103 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18349012 | METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R ANTAGONIST | HECK, BRYAN WILLIAM | 1643 | §102§103Other | Non-Final OA | 28d overdue | Pending | Jul 07, 2023 |
| 18345975 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | LIEB, JEANETTE M | 1654 | Other | Final Rejection | 3d overdue | Pending | Jun 30, 2023 |
| 18344494 | AUTO-INJECTOR AND RELATED METHODS OF USE | STIGELL, THEODORE J | 3783 | §102 | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18336644 | FAST PROTEIN SEQUENCING | CHEU, CHANGHWA J | 1678 | Other | Non-Final OA | 28d | Pending | Jun 16, 2023 |
| 18336148 | SYSTEMS AND METHODS FOR DRUG DELIVERY TO OCULAR TISSUE | MEDWAY, SCOTT J | 3783 | §102§103 | Final Rejection | 25d overdue | Pending | Jun 16, 2023 |
| 18328327 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | MERTZ, PREMA MARIA | 1674 | §112 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Non-Final OA | — | Pending | May 26, 2023 |
| 18202176 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | CANELLA, KAREN A | — | §102§103DP | Non-Final OA | — | Pending | May 25, 2023 |
| 18317241 | ANTI-LAG3 ANTIBODIES AND USES THEREOF | OUSPENSKI, ILIA I | 1644 | DP | Final Rejection | 52d overdue | Pending | May 15, 2023 |
| 18313745 | METHODS AND SYSTEMS FOR CHROMATOGRAPHY DATA ANALYSIS | TCHATCHOUANG, CARL F.R. | 2858 | DP | Non-Final OA | — | Pending | May 08, 2023 |
| 18142196 | Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations | HAMA, JOANNE | 1647 | §103Other | Non-Final OA | 8d overdue | Pending | May 02, 2023 |
| 18303229 | Rare Variants In Hematopoietic Stem Cells (HSC) And Hematopoietic Progenitor Cells (HPC) Associated With Somatic Alterations Of The Blood | SWITZER, JULIET CAROLINE | 1682 | §112 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18129923 | G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | MEYERING, SHABANA SHABBEER | 1635 | §102§103 | Non-Final OA | 62d | Pending | Apr 03, 2023 |
| 18247226 | COMBINATION OF ANTIBODIES FOR TREATING CANCER WITH REDUCED CYTOKINE RELEASE SYNDROME | STONEBRAKER, ALYSSA RAE | 1642 | DP | Final Rejection | — | Pending | Mar 29, 2023 |
| 18187564 | PRECISION DOSE DELIVERY DEVICE PLUNGER ROD INSERTION GAUGE AND METHODS THEREFOR | NGUYEN, ANDREW H | 3741 | §103§112 | Final Rejection | 2d overdue | Pending | Mar 21, 2023 |
| 18185624 | METHODS AND SYSTEMS FOR ANALYZING POLYPEPTIDE VARIANTS | NGUYEN, BAO THUY L | 1677 | §102§103§112DP | Final Rejection | 49d overdue | Pending | Mar 17, 2023 |
| 18182323 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 27d | Pending | Mar 11, 2023 |
| 18179110 | COMPOSITIONS AND METHODS COMPRISING ENGINEERED SHORT NUCLEAR RNA (SNRNA) | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Mar 06, 2023 |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | 4d overdue | Pending | Mar 02, 2023 |
| 18175809 | MANUFACTURING PROCESS FOR HIGH TITER ANTIBODY | MCKNIGHT, CIARA A | 1656 | §103§112DP | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18175852 | MANUFACTURING PROCESS FOR HIGH TITER ANTIBODY | GRIZER, CASSANDRA SENN | 1672 | §103§112DP | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18115321 | CELL CULTURE METHODS FOR ANTIBODY PRODUCTION | ARON, KIMBERLY A | 1633 | §102§103§112 | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18115285 | BIOREACTOR FOR ANTIBODY PRODUCTION | CANDELARIA, JULIANA IRENE | 1634 | §103 | Final Rejection | 21d | Pending | Feb 28, 2023 |
| 18175914 | MANUFACTURING PROCESS FOR HIGH TITER ANTIBODY | MCKNIGHT, CIARA A | 1656 | §103§112 | Non-Final OA | 83d | Pending | Feb 28, 2023 |
| 18114057 | Dosing Regimens for Mitigation of Cytokine Release Syndrome | SHUPE, ELIZABETH A | 1643 | §103§112DP | Non-Final OA | — | Pending | Feb 24, 2023 |
| 18108417 | Production of High Titer Recombinant Vesicular Stomatitis Virus in Suspension Cell Culture | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | — | Pending | Feb 10, 2023 |
| 18105772 | Stabilized Formulations Containing Anti-IL-33 Antibodies | KIM, YUNSOO | 1641 | §103 | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18164171 | MEDICAL DEVICE PACKAGING AND RELATED METHODS | REYNOLDS, STEVEN ALAN | 3735 | §102§112 | Final Rejection | 5d overdue | Pending | Feb 03, 2023 |
| 18163698 | ANTI-TFR:GAA AND ANTI-CD63:GAA INSERTION FOR TREATMENT OF POMPE DISEASE | JOHNSON, TIRONE DEREK | 1675 | §103§112 | Non-Final OA | — | Pending | Feb 02, 2023 |
| 18157587 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | CASH, KAILEY ELIZABETH | 1683 | §102§103DP | Final Rejection | 32d overdue | Pending | Jan 20, 2023 |
| 18154262 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | SKOKO III, JOHN JOSEPH | 1643 | §103 | Non-Final OA | — | Pending | Jan 13, 2023 |
| 18095839 | Methods for Improving Resolution of Heterodimeric Proteins from Impurities Using Affinity Chromatography | IANNUZO, NATALIE NMN | 1653 | §103 | Final Rejection | — | Pending | Jan 11, 2023 |
| 18152346 | Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) Variants And Uses Thereof | SALMON, KATHERINE D | 1682 | §102§103§112 | Final Rejection | — | Pending | Jan 10, 2023 |
| 18089267 | HUMANIZED RODENTS FOR TESTING THERAPEUTIC AGENTS | WILSON, MICHAEL C | 1638 | §103§112 | Final Rejection | — | Pending | Dec 27, 2022 |
| 18069110 | OFF-TARGET PREDICTION METHOD FOR ANTIGEN-RECOGNITION MOLECULES BINDING TO MHC-PEPTIDE TARGETS | LEVERETT, MARY CHANG | 1687 | §103 | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18055895 | AUTO-INJECTOR AND RELATED METHODS OF USE | GONZALEZ, LEI NMN | 3783 | §103 | Non-Final OA | 39d | Pending | Nov 16, 2022 |
| 18049834 | OVEREXPRESSION OF LEMD2, LEMD3, OR CHMP7 AS A THERAPEUTIC MODALITY FOR TAUOPATHY | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | — | Pending | Oct 26, 2022 |
| 17973638 | SYSTEMS AND METHODS FOR GENERATING LABORATORY WATER AND DISTRIBUTING LABORATORY WATER AT DIFFERENT TEMPERATURES | GURTOWSKI, RICHARD C | 1773 | §103 | Non-Final OA | 6d | Pending | Oct 26, 2022 |
| 17920069 | NON-HUMAN ANIMALS HAVING A HUMANIZED CXCL13 GENE | DHAR, MATASHA | 1632 | §103 | Non-Final OA | 46d overdue | Pending | Oct 20, 2022 |
| 18045603 | MUSCLE BLOCKS AND INJECTION TRAINERS INCLUDING A MUSCLE BLOCK | ANTOINE, LISA HOPE | 3715 | §103 | Non-Final OA | — | Pending | Oct 11, 2022 |
| 17954999 | ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS | EVANS, CHRISTOPHER RYAN | 1677 | §102§103§112 | Final Rejection | 4d overdue | Pending | Sep 28, 2022 |
| 17934277 | Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes | KENYON, JOHN S | 1625 | §112 | Non-Final OA | 49d overdue | Pending | Sep 22, 2022 |
| 17948496 | METHODS FOR CHARACTERIZING HOST-CELL PROTEINS | BERKELEY, EMILY R | 1796 | §102§103§112 | Non-Final OA | 32d overdue | Pending | Sep 20, 2022 |
| 17948382 | METHODS OF CONTROLLING ANTIBODY HETEROGENEITY | O'NEILL, MARISOL ANN | 1633 | §103 | Non-Final OA | — | Pending | Sep 20, 2022 |
| 17933148 | ANTI-C5 ANTIBODIES AND USES THEREOF | ALAWADI, SARAH | 1619 | §112 | Non-Final OA | — | Pending | Sep 19, 2022 |
| 17943776 | NMASS SPECTROMETRY-BASED STRATEGY FOR CHARACTERIZING HIGH MOLECULAR WEIGHT SPECIES OF A BIOLOGIC | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §103 | Non-Final OA | — | Pending | Sep 13, 2022 |
| 17931396 | Methods Of Treating Clonal Hematopoiesis Of Indeterminate Potential (CHIP) With Lymphocyte Antigen 75 (LY75), Cluster Of Differentiation 164 (CD164), Or Poly(ADP-Ribose) Polymerase 1 (PARP1) Inhibitors | DARPOLOR, JOSEPHINE KEBBEH | 1642 | §103§112 | Non-Final OA | — | Pending | Sep 12, 2022 |
| 17930471 | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS | XU, XIAOYUN | 1797 | §103 | Non-Final OA | — | Pending | Sep 08, 2022 |
| 17759539 | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS COMPRISING A V30M MUTATION AND METHODS OF USE | PENNINGTON, KATIE LEIGH | 1634 | §103§112 | Final Rejection | — | Pending | Jul 27, 2022 |
| 17870368 | NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY | XU, XIAOYUN | 1797 | §103Other | Final Rejection | 55d | Pending | Jul 21, 2022 |
| 17868305 | Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format | NATARAJAN, MEERA | 1643 | §103§112 | Non-Final OA | — | Pending | Jul 19, 2022 |
| 17813100 | COMBINATION OF CHECKPOINT INHIBITORS AND AN ONCOLYTIC VIRUS FOR TREATING CANCER | MOSELEY II, NELSON B | 1642 | §103 | Final Rejection | — | Pending | Jul 18, 2022 |
| 17862240 | Methods for Viral Particle Characterization Using Two-Dimensional Liquid Chromatography-Mass Spectrometry | ZOU, NIANXIANG | 1671 | §103§112 | Final Rejection | 20d | Pending | Jul 11, 2022 |
| 17854589 | Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors | VYAS, KEYUR ANILKUMAR | 1637 | §101§112 | Non-Final OA | 19d overdue | Pending | Jun 30, 2022 |
| 17853807 | COUPLING ISOELECTRIC FOCUSING-BASED FRACTIONATION WITH MASS SPECTROMETRY ANALYSIS | SIMMONS, VALERIE MICHELLE | 1758 | §103 | Non-Final OA | — | Pending | Jun 29, 2022 |
| 17851845 | NMR METHODS FOR ANTIBODY HIGHER ORDER STRUCTURE COMPARABILITY | BERKELEY, EMILY R | 1796 | §101§102§103 | Non-Final OA | — | Pending | Jun 28, 2022 |
| 17719791 | TREATMENT OF X-LINKED JUVENILE RETINOSCHISIS | LEVIN, JOEL D | 1633 | §102§103 | Non-Final OA | — | Pending | Apr 13, 2022 |
| 17716154 | MEASUREMENT OF THERAPEUTIC PROTEINS CO-ADMINISTERED TO A SUBJECT BY LC-MRM-MS ASSAY | CONSTANTINE, CHARLES Z | 1657 | §103§112 | Final Rejection | — | Pending | Apr 08, 2022 |
| 17656617 | METHODS AND SYSTEMS FOR DEVELOPING MIXING PROTOCOLS | DEBNATH, NUPUR | 2186 | §103§112 | Final Rejection | — | Pending | Mar 25, 2022 |
| 17684674 | SYSTEMS AND METHODS FOR QUANTIFYING AND MODIFYING PROTEIN VISCOSITY | XU, XIAOYUN | 1797 | §103 | Non-Final OA | 31d overdue | Pending | Mar 02, 2022 |
| 17676338 | NON-HUMAN ANIMALS HAVING AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION THAT INCLUDES AN ENGINEERED DIVERSITY CLUSTER AND USES THEREOF | WILSON, MICHAEL C | 1638 | §112 | Final Rejection | 100d overdue | Pending | Feb 21, 2022 |
| 17591355 | Systems and Methods for Sequencing T Cell Receptors and Uses Thereof | ZEMAN, MARY K | 1686 | DP | Non-Final OA | — | Pending | Feb 02, 2022 |
| 17575450 | HUMANIZED T CELL MEDIATED IMMUNE RESPONSES IN NON-HUMAN ANIMALS | MOLOYE, TITILAYO | 1632 | Other | Final Rejection | — | Pending | Jan 13, 2022 |
| 17565104 | AUTO-INJECTOR AND RELATED METHODS OF USE | ZAMORY, JUSTIN L | 3783 | §102§103 | Non-Final OA | 22d | Pending | Dec 29, 2021 |
| 17612669 | MODIFIED VIRAL PARTICLES AND USES THEREOF | RIGA, MICHAEL ANGELO | 1634 | §102 | Non-Final OA | — | Pending | Nov 19, 2021 |
| 17612204 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Final Rejection | — | Pending | Nov 17, 2021 |
| 17525336 | Synaptojanin 2 (SYNJ2) Variants And Uses Thereof | POHNERT, STEVEN C | 1683 | §103§112 | Non-Final OA | — | Pending | Nov 12, 2021 |
| 17517294 | METHODS AND SYSTEMS FOR BIOTHERAPEUTIC DEVELOPMENT | SANFORD, DIANA PATRICIA | 1687 | §101§103 | Non-Final OA | — | Pending | Nov 02, 2021 |
| 17492490 | CONTINUOUS VIRUS RETENTIVE FILTRATION | PEO, KARA M | 1777 | §103§112 | Final Rejection | — | Pending | Oct 01, 2021 |
| 17476078 | Use of LEPR Agonists for Pain | CHERNYSHEV, OLGA N | 1675 | §112 | Final Rejection | — | Pending | Sep 15, 2021 |
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | LEONARD, ARTHUR S | 1631 | §103§112 | Final Rejection | 6d | Pending | Aug 25, 2021 |
| 17444897 | SYSTEMS AND METHODS FOR DRUG DELIVERY TO OCULAR TISSUE | PAZ ESTEVEZ, GUILLERMO G | 3783 | §103 | Final Rejection | — | Pending | Aug 11, 2021 |
| 17356497 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | CANELLA, KAREN A | 1643 | §102§112 | Final Rejection | 8d | Pending | Jun 23, 2021 |
| 17244864 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | HOPKINS, SAMANTHA LAKE | 1641 | §103§112Other | Final Rejection | — | Pending | Apr 29, 2021 |
| 17203566 | TARGET INTERFERENCE MITIGATION IN ANTI-DRUG ANTIBODY ASSAY | HAQ, SHAFIQUL | 1678 | §112 | Non-Final OA | — | Pending | Mar 16, 2021 |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | FAUST, AMBER KATHLEEN | 1643 | §103 | Non-Final OA | 33d | Pending | Feb 24, 2021 |
| 17268719 | METHOD AND CHROMATOGRAPHY SYSTEM FOR DETERMINING AMOUNT AND PURITY OF A MULTIMERIC PROTEIN | GERMAIN, ADAM ADRIEN | 1777 | §103 | Final Rejection | — | Pending | Feb 16, 2021 |
| 17113485 | GENETICALLY MODIFIED MICE THAT EXPRESS HUMANIZED IgG1 LACKING A CH1 DOMAIN AND HUMANIZED UNIVERSAL LIGHT CHAIN | WILSON, MICHAEL C | 1638 | §112 | Final Rejection | — | Pending | Dec 07, 2020 |
| 17091484 | Accurate And Robust Information-Deconvolution From Bulk Tissue Transcriptomes | STRIEGEL, THEODORE CHARLES | 1685 | §103 | Final Rejection | 3d overdue | Pending | Nov 06, 2020 |
| 17062375 | High-throughput method to screen cognate T cell and epitope reactivities in primary human cells | YOUNG, BRIAN ELLIS | 1684 | §103 | Final Rejection | 30d | Pending | Oct 02, 2020 |
| 16993434 | HIGH CONCENTRATION ANTI-C5 FORMULATIONS | ESSEX, LAURA ANN | 1675 | §103§112 | Non-Final OA | 53d | Pending | Aug 14, 2020 |
| 16882453 | CHARACTERIZATION OF DOMAIN-SPECIFIC CHARGE VARIANTS OF ANTIBODIES | NGUYEN, HENRY H | 1758 | §101§103§112 | Non-Final OA | — | Pending | May 23, 2020 |
| 16880736 | METHODS FOR IDENTIFYING AND QUANTITATING HOST CELL PROTEIN | MARCSISIN, ELLEN JEAN | 1677 | §103 | Non-Final OA | — | AI Ready | May 21, 2020 |
| 16863800 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST | JOHANSEN, PETER N. | 1644 | §103Other | Final Rejection | — | Pending | Apr 30, 2020 |
| 16625207 | Tropism-Modified Recombinant Viral Particles and Uses Thereof for the Targeted Introduction of Genetic Material into Human Cells | GROOMS, TIFFANY NICOLE | 1637 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2019 |
| 16278611 | GAN-CNN FOR MHC PEPTIDE BINDING PREDICTION | BICKHAM, DAWN MARIE | 1685 | §101§103§112 | Final Rejection | — | Pending | Feb 18, 2019 |
| 15766586 | STABLE PROTEIN COMPOSITIONS | SAEED, ALI S | 1616 | §103§112 | Non-Final OA | 83d | Pending | Apr 06, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial